7.53
price up icon1.76%   0.13
after-market アフターアワーズ: 7.53
loading
前日終値:
$7.40
開ける:
$7.32
24時間の取引高:
3.99M
Relative Volume:
1.23
時価総額:
$1.47B
収益:
$331.41M
当期純損益:
$-226.54M
株価収益率:
-6.3814
EPS:
-1.18
ネットキャッシュフロー:
$-97.31M
1週間 パフォーマンス:
+6.96%
1か月 パフォーマンス:
-5.64%
6か月 パフォーマンス:
+0.13%
1年 パフォーマンス:
+69.98%
1日の値動き範囲:
Value
$7.25
$7.76
1週間の範囲:
Value
$6.96
$7.76
52週間の値動き範囲:
Value
$4.03
$9.50

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
名前
Biocryst Pharmaceuticals Inc
Name
セクター
Healthcare (1182)
Name
電話
919-859-1302
Name
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
職員
580
Name
Twitter
@biocrystpharma
Name
次回の収益日
2025-02-24
Name
最新のSEC提出書
Name
BCRX's Discussions on Twitter

BCRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
7.53 1.47B 331.41M -226.54M -97.31M -1.18
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.85 67.28B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.19 45.61B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.93 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.31 15.64B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
284.25 12.77B 2.76B 1.11B 898.10M 22.77

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-25 開始されました Wedbush Outperform
2023-11-20 再開されました JP Morgan Overweight
2023-09-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-08-04 アップグレード Jefferies Hold → Buy
2023-07-13 アップグレード BofA Securities Neutral → Buy
2023-02-22 アップグレード Needham Hold → Buy
2022-11-02 アップグレード Evercore ISI In-line → Outperform
2022-08-05 ダウングレード Evercore ISI Outperform → In-line
2022-08-05 ダウングレード Oppenheimer Outperform → Perform
2022-04-18 ダウングレード Barclays Overweight → Equal Weight
2022-04-11 ダウングレード BofA Securities Buy → Neutral
2021-12-10 開始されました Oppenheimer Outperform
2021-08-06 ダウングレード Jefferies Buy → Hold
2021-08-03 開始されました Cantor Fitzgerald Overweight
2021-03-01 開始されました Cowen Outperform
2020-09-29 再開されました JP Morgan Overweight
2020-06-17 開始されました BTIG Research Neutral
2020-05-05 アップグレード Barclays Equal Weight → Overweight
2019-11-15 アップグレード BofA/Merrill Neutral → Buy
2019-05-24 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-11-16 再開されました Piper Jaffray Overweight
2018-08-08 再開されました JP Morgan Overweight
2018-07-17 アップグレード BofA/Merrill Underperform → Neutral
2018-06-22 開始されました Seaport Global Securities Neutral
2018-01-02 アップグレード RBC Capital Mkts Sector Perform → Outperform
2017-12-20 開始されました Barclays Equal Weight
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-09-06 アップグレード JP Morgan Neutral → Overweight
2017-09-06 アップグレード Jefferies Hold → Buy
2017-02-16 開始されました Ladenburg Thalmann Buy
2016-08-12 アップグレード Piper Jaffray Neutral → Overweight
2016-08-04 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました FBR Capital Outperform
2016-02-09 ダウングレード JP Morgan Overweight → Neutral
2016-02-09 ダウングレード Needham Buy → Hold
すべてを表示

Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース

pulisher
07:17 AM

BioCryst to Report First Quarter 2025 Financial Results on May 5 | BCRX Stock News - GuruFocus

07:17 AM
pulisher
07:14 AM

BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025 - Nasdaq

07:14 AM
pulisher
07:02 AM

BioCryst to Report First Quarter 2025 Financial Results on May 5 - GlobeNewswire

07:02 AM
pulisher
07:00 AM

BioCryst Earnings Preview: Key Financial Updates and Corporate Strategy Reveal Coming May 5 - Stock Titan

07:00 AM
pulisher
Apr 20, 2025

Where are the Opportunities in (BCRX) - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 17, 2025

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st

Apr 17, 2025
pulisher
Apr 11, 2025

BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst appoints interim CFO following executive departure - Investing.com

Apr 10, 2025
pulisher
Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition - Investing.com

Apr 09, 2025
pulisher
Apr 04, 2025

(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 04, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

BioCryst to Present at Upcoming Investor Conference - The Manila Times

Apr 03, 2025
pulisher
Apr 02, 2025

BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.

Apr 02, 2025
pulisher
Apr 01, 2025

Biocryst discovers new KLK5 inhibitors - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 27, 2025

BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews

Mar 27, 2025
pulisher
Mar 19, 2025

North Carolina biotech sues to block copies of $400M drug - The Business Journals

Mar 19, 2025
pulisher
Mar 18, 2025

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego

Mar 18, 2025
pulisher
Mar 18, 2025

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St

Mar 18, 2025
pulisher
Mar 14, 2025

(BCRX) Technical Data - news.stocktradersdaily.com

Mar 14, 2025
pulisher
Mar 14, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst sues to protect ORLADEYO patents - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com

Mar 11, 2025
pulisher
Mar 09, 2025

Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com

Mar 09, 2025
pulisher
Mar 09, 2025

Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst reports inducement grants under Nasdaq listing rule - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

CFO Anthony Doyle resigns at Biocryst - biocentury.com

Mar 05, 2025

Biocryst Pharmaceuticals Inc (BCRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$8.48
price up icon 0.47%
$27.00
price up icon 0.00%
$100.62
price down icon 0.69%
$7.57
price up icon 0.13%
$100.68
price down icon 0.69%
$284.25
price down icon 0.17%
大文字化:     |  ボリューム (24 時間):